The part of the clinical trial that is most important to me is the said adverse effects that were found in the patients who participated in the study. Based on the concluding trial results, the adverse effects of the drug is said to be the same as the placebo. That's great news. I'm going to continue to watch this drug for new updates and news pertaining to safety. So far, this new treatment by Takeda Pharmaceuticals looks promising.
I have also included the clinical trial abstract below.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
- Inhibition of leukocyte trafficking in inflammatory bowel disease. [N Engl J Med. 2013]
- [PubMed - indexed for MEDLINE]